Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder. Rejoyn (formerly CT-152), a ...

Otsuka Pharma and Click Therapeutics' Rejoyn (formerly CT-152) app – which is used to help people with MDD manage their emotions more effectively – can be unlocked with a prescription from a ...